The biotech company Enzymatica announces that turnover for 2013 will heavily exceed the financial goal of SEK 7 million that the company wrote about in the year-end report for 2012. The preliminary figures for 2013 show that Enzymatica will have a turnover of SEK 10.5 million (SEK 0.9 million), which is more than 50 percent above the financial goal. For the forth quarter of 2013 turnover is estimated to amount to SEK 6.0 million (SEK 0.4 million). The successful launch of ColdZyme®Mouthspray against common cold in the Swedish market explains the favorable development of sales. During the year Enzymatica has concluded agreements with most of the pharmacy chains in the country. During the autumn the company has conducted a comprehensive market campaign, which has put ColdZyme in the top ten list of most sold products against common cold in value.
As previously announced Enzymatica will publish its year-end report for 2013 on February 4th, 2014 with complete figures for the financial development.
Figures within parenthesis above specify the turnover for 2012 respectively for the forth quarter of 2012.
For further information about Enzymatica, please contact:
Michael Edelborg Christensen, CEO Enzymatica AB (publ), +46 768-14 41 66, firstname.lastname@example.org
About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.